Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 846

Sort by

Sort Order Select

Journal Articles

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Hong Yin, MD PhD, Yi Huo, PhD, Zhen Sheng, PhD, Chi-Ming Li, PhD, Daniel C Ellwanger, PhD, Daniel Lu, PhD, Oliver Homann, PhD, Songli Wang, MD PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3886.

https://doi.org/10.1182/blood-2019-124636

Published: 2019

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Young Rok Do, PhDMD, Sang Yun Song, MD PhD, Ga-Young Song, Hyeong Jong Kim, MD, Theresa Kim

Blood (2019) 134 (Supplement_1): 2329.

https://doi.org/10.1182/blood-2019-126533

Published: 2019

Journal Articles

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Theodora Anagnostou, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Shahrzad Jalali, PhD, Jose C Villasboas, Hongyan Wu, PhD, Tammy Price-Troska, BS, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2790.

https://doi.org/10.1182/blood-2019-127757

Published: 2019

Journal Articles

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Haider Ghiasuddin, Adam Morin, Marzia Capelletti, PhD MMSc, Shira Orr, PhD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 2673.

https://doi.org/10.1182/blood-2019-131491

Published: 2019

Journal Articles

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

C. Chris Huang, PhD, Yumi Nakayama, PhD, Matthew Stokes, PhD, Fadi Towfic, PhD, chung-Wein Lee, Yan Ren, Mathieu Marella, PhD, Maria Wang, Patrick R. Hagner, PhD, Suzana Couto, Kathryn Newhall, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 2797.

https://doi.org/10.1182/blood-2019-123691

Published: 2019

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients

Xiaoyan Feng, Yue Song, Zhaoming Li, MD PhD, Xudong Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 3969.

https://doi.org/10.1182/blood-2019-128622

Published: 2019

Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 4064.

https://doi.org/10.1182/blood-2019-124886

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD

Blood (2019) 134 (Supplement_1): 4041.

https://doi.org/10.1182/blood-2019-127278

Published: 2019

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Blood (2019) 134 (Supplement_1): 4458.

https://doi.org/10.1182/blood-2019-126022

Published: 2019

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

NARROW

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only